MCID: VSC006
MIFTS: 52

Vascular Cancer

Categories: Cardiovascular diseases, Cancer diseases, Nephrological diseases, Blood diseases

Aliases & Classifications for Vascular Cancer

MalaCards integrated aliases for Vascular Cancer:

Name: Vascular Cancer 12 14
Malignant Vascular Neoplasm 12 69
Renal Vein Leiomyosarcoma 12 69
Blood Vessel Tumors 12 52
Vascular Neoplasms 42 69
Malignant Tumor of Pulmonary Artery 12
Pulmonary Artery Malignant Neoplasm 12
Malignant Neoplasm of Great Vessels 69
Malignant Tumor of Pulmonary Vein 12
Pulmonary Vein Malignant Neoplasm 12
Leiomyosarcoma of the Renal Vein 12
Blood Vessel Tumour Disorder 12
Malignant Great Vessel Tumor 12
Neoplasms, Vascular Tissue 69
Malignant Vascular Tumor 12
Neoplasm of Great Vessel 12
Vascular Tissue Neoplasm 12
Haemangiomatous Tumour 12
Blood Vessel Neoplasm 12
Blood Vessel Cancer 69
Blood Vessel Tumor 12
Vascular Tumors 12

Classifications:



Summaries for Vascular Cancer

Disease Ontology : 12 A cardiovascular cancer that is located in blood vessels.

MalaCards based summary : Vascular Cancer, also known as malignant vascular neoplasm, is related to angiosarcoma and kaposiform hemangioendothelioma. An important gene associated with Vascular Cancer is FLT4 (Fms Related Tyrosine Kinase 4), and among its related pathways/superpathways are TGF-Beta Pathway and Akt Signaling. The drugs Ethanol and Heparin have been mentioned in the context of this disorder. Affiliated tissues include lung, bone and liver, and related phenotypes are cardiovascular system and hematopoietic system

Related Diseases for Vascular Cancer

Diseases related to Vascular Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 93)
id Related Disease Score Top Affiliating Genes
1 angiosarcoma 11.2
2 kaposiform hemangioendothelioma 11.1
3 hemangioendothelioma 11.1
4 spindle cell hemangioma 11.1
5 hemangioma 11.0
6 hypertonia 10.7 FLT4 VEGFA
7 breast angiosarcoma 10.7
8 glomeruloid hemangioma 10.7
9 hemangioma, capillary infantile 10.7 FLT4 KDR
10 carotid body cancer 10.6
11 colorectal adenoma 10.6 FGF2 VEGFA
12 iliac vein thrombophlebitis 10.6 KDR VEGFA
13 benign familial neonatal epilepsy 10.5 FLT4 KDR VEGFA
14 epidural neoplasm 10.5 VEGFA VWF
15 trachea carcinoma in situ 10.5 FLT4 KDR VEGFA
16 conventional angiosarcoma 10.5 HBA1 VEGFA
17 striatonigral degeneration 10.5 CAMTA1 HBA1
18 papillary meningioma of the cerebellum 10.5 FLT4 HBA1
19 segmental odontomaxillary dysplasia 10.5 FGF2 KDR VEGFA
20 phalanx chondroma 10.4 ENG KDR
21 peroxisomal biogenesis disorders 10.4 FLT1 VEGFA
22 kidney pelvis papillary carcinoma 10.4 FLT1 KDR VEGFA
23 thyroid sarcoma 10.4 CAMTA1 HBA1
24 lens disease 10.4 FLT1 KDR VEGFA
25 acitretin/etretinate embryopathy 10.4 FLT1 VEGFA
26 hidradenoma 10.4 FLT1 KDR VEGFA
27 albinism, oculocutaneous, type ia 10.4 FLT1 KDR VEGFA
28 ulnar neuropathy 10.4 FLT1 VEGFA
29 punctate palmoplantar keratoderma type 2 10.4 KDR KIT
30 neuropathy, hereditary sensory and autonomic, type vi 10.3 FGF2 FLT1 VEGFA
31 wilms tumor 6 10.3 KIT PDGFRB
32 desmoplastic small round cell tumor 10.3 KIT PDGFRB
33 dermoid cyst 10.3 HBA1 VWF
34 hemi 3 syndrome 10.3 CAMTA1 FLI1 FLT4 KDR
35 extragonadal germ cell cancer 10.3 HBA1 KDR VEGFA
36 preeclampsia/eclampsia 1 10.2 ENG FLT1 VEGFA
37 lipoic acid synthetase deficiency 10.2 FLT1 VEGFA
38 hematopoietic stem cell transplantation 10.2 FGF2 FLT4 KDR VEGFA
39 pleural tuberculosis 10.2 ENG FLT1 VEGFA
40 coloboma of superior eyelid 10.2 CAMTA1 FLT1 KDR VEGFA
41 hyperlucent lung 10.2 FLT1 FLT4 HBA1
42 ovarian brenner tumor 10.2 FGF2 FLT4 KDR VEGFA
43 cask-related intellectual disability 10.2 KDR KIT PDGFRB
44 extraosseous osteosarcoma 10.2 KDR KIT PDGFRB
45 sydenham chorea 10.1 ENG FLT1
46 holoprosencephaly 10.1 ENG VEGFA VWF
47 thyroid angiosarcoma 10.1 HBA1 KIT
48 crohn disease-associated growth failure 10.1 THBS1 VEGFA
49 adenoma 10.1 THBS1 VEGFA
50 fuhrmann syndrome 10.1 FGF2 KDR PDGFRB VEGFA

Graphical network of the top 20 diseases related to Vascular Cancer:



Diseases related to Vascular Cancer

Symptoms & Phenotypes for Vascular Cancer

MGI Mouse Phenotypes related to Vascular Cancer:

44 (show all 17)
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.35 ENG FGF2 FLI1 FLT1 FLT4 KDR
2 hematopoietic system MP:0005397 10.25 THBS1 VEGFA VWF ANPEP ENG FGF2
3 growth/size/body region MP:0005378 10.22 CAMTA1 ENG FLI1 FLT1 FLT4 KDR
4 cellular MP:0005384 10.21 FGF2 FLI1 FLT1 KDR KIT PDGFRB
5 homeostasis/metabolism MP:0005376 10.19 ENG FGF2 FLT1 FLT4 KDR KIT
6 immune system MP:0005387 10.18 ANPEP FLI1 FLT1 FLT4 KDR KIT
7 mortality/aging MP:0010768 10.18 CAMTA1 ENG FGF2 FLI1 FLT1 FLT4
8 embryo MP:0005380 10.14 ENG FLI1 FLT1 FLT4 KDR KIT
9 digestive/alimentary MP:0005381 10.09 VWF ENG FLT4 KIT PDGFRB THBS1
10 muscle MP:0005369 10.07 ENG FGF2 FLI1 FLT1 FLT4 KDR
11 integument MP:0010771 10.06 ANPEP ENG FLT4 KDR KIT PDGFRB
12 nervous system MP:0003631 9.96 CAMTA1 ENG FGF2 FLI1 FLT1 KDR
13 liver/biliary system MP:0005370 9.91 FLI1 FLT4 KDR KIT THBS1 VEGFA
14 neoplasm MP:0002006 9.8 CAMTA1 FGF2 FLI1 KIT THBS1 VEGFA
15 normal MP:0002873 9.76 FLT4 KDR KIT PDGFRB VEGFA CAMTA1
16 reproductive system MP:0005389 9.61 ANPEP CAMTA1 FGF2 FLT1 FLT4 KIT
17 vision/eye MP:0005391 9.23 ANPEP FGF2 FLT1 KDR KIT PDGFRB

Drugs & Therapeutics for Vascular Cancer

Drugs for Vascular Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1044)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethanol Approved Phase 4,Phase 2,Phase 3,Phase 1 64-17-5 702
2
Heparin Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 9005-49-6 772 46507594
3
Dopamine Approved Phase 4,Phase 1,Phase 2 51-61-6, 62-31-7 681
4
Nitric Oxide Approved Phase 4,Phase 1 10102-43-9 145068
5
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 50-02-2 5743
6
Doxorubicin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 23214-92-8 31703
7
Simvastatin Approved Phase 4,Phase 3,Phase 2,Early Phase 1 79902-63-9 54454
8
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 104987-11-3 445643 439492
9
Aspirin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 50-78-2 2244
10
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
11
Etoposide Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 33419-42-0 36462
12
Cisplatin Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 15663-27-1 84093 441203 2767
13
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
14
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
15
Iron Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 7439-89-6 23925
16
Gemcitabine Approved Phase 4,Phase 2,Phase 3,Phase 1 95058-81-4 60750
17
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1 24280-93-1 446541
18
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 128794-94-5 5281078
19
Morphine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 57-27-2 5288826
20
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
21
Amlodipine Approved Phase 4 88150-42-9 2162
22
Sorafenib Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 284461-73-0 216239 406563
23
Histamine Approved, Investigational Phase 4,Phase 2 75614-87-8, 51-45-6 774
24
Bromocriptine Approved, Investigational Phase 4 25614-03-3 31101
25
Famotidine Approved Phase 4,Phase 2 76824-35-6 3325
26
Infliximab Approved Phase 4,Phase 2,Phase 1 170277-31-3
27
Amiloride Approved Phase 4 2016-88-8, 2609-46-3 16231
28
Hydroxychloroquine Approved Phase 4,Phase 1,Phase 2 118-42-3 3652
29
Bortezomib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 179324-69-7 387447 93860
30
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
31
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
32
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61825-94-3 5310940 9887054 43805 6857599
33
Basiliximab Approved, Investigational Phase 4,Phase 2,Phase 3 152923-56-3, 179045-86-4
34
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 159351-69-6 6442177
35
Lenograstim Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 135968-09-1
36
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7 4594 9579578
37 Nadroparin Approved Phase 4,Phase 3 9041-08-1
38
Telbivudine Approved, Investigational Phase 4 3424-98-4 159269
39
Ranibizumab Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 347396-82-1 459903
40
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
41
Dalteparin Approved Phase 4,Phase 3,Phase 1,Phase 2 9005-49-6
42
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1 51-21-8 3385
43
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 216974-75-3
44
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53123-88-9 5284616 6436030 46835353
45
Epirubicin Approved Phase 4,Phase 2,Phase 3,Phase 1 56420-45-2 41867
46
Pancrelipase Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 53608-75-6
47
Ethiodized oil Approved Phase 4,Phase 2,Phase 3,Phase 1 8008-53-5
48
Norepinephrine Approved Phase 4,Phase 3 51-41-2 439260
49
Glyburide Approved Phase 4 10238-21-8 3488
50
Pioglitazone Approved, Investigational Phase 4,Phase 2,Phase 1 111025-46-8 4829

Interventional clinical trials:

(show top 50) (show all 3708)

id Name Status NCT ID Phase Drugs
1 Study of Concurrent Chemo-radiotherapy Combined With Recombinant Human Endostatin for Local Advanced Non-small Cell Lung Cancer (NSCLC) Unknown status NCT01211002 Phase 4 radiotherapy / EP combined with recombinant human endostatin
2 Residual Vein Thrombosis and the Optimal Duration of Low Molecular Weight Heparin in Cancer Patients With Deep Vein Thrombosis Unknown status NCT00450645 Phase 4 low molecular weight heparin
3 Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using Transcatheter Arterial Chemoembolization (TACE) With Anti-hepatitis B Virus (Anti-HBV) Therapy Unknown status NCT01102335 Phase 4 Telbivudine
4 Esomeprazole or Famotidine in the Management of Aspirin Related Non-Ulcer Dyspepsia Unknown status NCT00978159 Phase 4 esomeprazole;Famotidine
5 Steroid Free Immunosuppression or Calcineurin Inhibitor Minimization After Basiliximab Induction Therapy in Kidney Transplantation: Comparison With a Standard Quadruple Immunosuppressive Regimen Unknown status NCT01560572 Phase 4 tacrolimus OD, mycophenolic acid, prednisolone
6 Study Effects of Ginkgo Biloba Extract on Endothelial Cell Function and Genetic Effects on the Response to Ginkgo Biloba Extract in Diabetic Patients With Stable Coronary Artery Disease Unknown status NCT01038050 Phase 4 Ginkgo Biloba Extract (GBE)
7 Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy Unknown status NCT00540930 Phase 4 Ranibizumab
8 Hepatic Resection Versus Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Complicated by Portal Vein Tumor Thrombosis Unknown status NCT01350206 Phase 4
9 Effects of Angiotensin II Receptor Blocker Compared With Diuretics in High-risk Hypertensive Patients Unknown status NCT01011660 Phase 4 Amlodipine, Telmisartan, Amiloride Compound , Simvastatin
10 The Therapeutic Effect of Bromocriptin in Patients With Primary Aldosteronism Unknown status NCT00451672 Phase 4 bromocriptine
11 HOPE-2 Study (Heart Outcomes Prevention Evaluation-2 Study) Unknown status NCT00106886 Phase 4 Folic acid, vitamin B6 and B12 or placebo
12 Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma Unknown status NCT01249690 Phase 4 Bortezomib,Pirarubicin,Dexamethasone;Thalidomide,Pirarubicin,Dexamethasone
13 LigaSure Small Jaw® Versus Conventional Neck Dissection in Head and Neck Cancer Patients Completed NCT02597582 Phase 4
14 Recombinant Human Endostatin Combined With NP in Neoadjuvant Chemotherapy of Stage ⅢA NSCLC Completed NCT02497118 Phase 4 Endostatin;Vinorelbine;Cisplatin
15 Assessment of the Effects of Pressors on Graft Blood Flow After Free Tissue Transfer Surgery Completed NCT01418118 Phase 4 Epinephrine;Norepinephrine;Dobutamine;Dopexamine
16 Vascular Endothelial Protection Effects of Dextromethorphan Completed NCT00605605 Phase 4 Dextromethorphan
17 Open-label Study in Patients With Metastatic NSLC Treated With Cisplatin, Gemcitabine and Bevacizumab Completed NCT02316327 Phase 4 gemcitabine, cisplatin and bevacizumab
18 A Comparison of Dermal Autograft to AlloDerm in Breast Reconstruction Completed NCT01561287 Phase 4
19 An Observational Study of Patient Cohorts Who Previously Received Long-term Treatment With Pioglitazone or Placebo in Addition to Existing Antidiabetic Medications Completed NCT02678676 Phase 4
20 VEG113971: An Open-Label Study of the Effects of Ketoconazole or Esomeprazole on Pazopanib PK Completed NCT01205230 Phase 4 pazopanib
21 Vascular Endothelial Growth Factor in Stage V ROP Completed NCT00500396 Phase 4
22 Effect of Pioglitazone on TIMP-3 and TACE in Type 2 Diabetes Completed NCT01223196 Phase 4 Pioglitazone;Placebo
23 Decreasing Postoperative Complications by Goal-Directed Fluid Therapy During Esophageal Resection Completed NCT01416077 Phase 4
24 Outcome of Transarterial Chemo-embolization (TACE) in Hepatocellular Carcinoma Patients With Partial Portal Vein Thrombosis Completed NCT03007212 Phase 4
25 Effect of 5 Years of GH Replacement on Atherosclerosis Completed NCT00462475 Phase 4 Recombinant Growth Hormone, Genotropin (Pfizer)
26 Anti-Inflammatory Actions of Valsartan in Patients With Type 2 Diabetes Mellitus Completed NCT00982358 Phase 4 Valsartan
27 Traditional (Traditional Chemoembolization) TACE Versus Microsphere TACE Completed NCT00936689 Phase 4
28 Study in Cancer Patients With Central Line Associated Clots in the Upper Extremity Treated With Rivaroxaban (Catheter 2) Completed NCT01708850 Phase 4 Rivaroxaban
29 A Prospective Study Comparing Contour SE™ Microspheres to Embosphere® Microspheres for Treating Symptomatic Uterine Fibroids With Uterine Fibroid Embolization (UFE) Completed NCT00628901 Phase 4
30 Rivaroxaban for the Prevention of Venous Thromboembolism in Asian Patients With Cancer Completed NCT01989845 Phase 4 Rivaroxaban
31 Efficacy and Safety of Drug Eluting Beads TACE in Treatment of HCC in Egyptian Patients Completed NCT03007225 Phase 4 Trans-arterial chemoembolization (TACE);TACE with Drug Eluting Beads procedure
32 Cancer Venous Thromboembolism (VTE) Completed NCT02073682 Phase 4 Edoxaban;Dalteparin
33 LUCAS (Lucentis Compared to Avastin Study) Completed NCT01127360 Phase 4 Bevacizumab;Ranibizumab
34 Efficacy and Safety of Pioglitazone in Treating Subjects With Vascular Complications Associated With Type 2 Diabetes Mellitus. Completed NCT00770835 Phase 4 Pioglitazone and Metformin;Glibenclamide and Metformin
35 Harmonic ACE®+7 Shears in Laparoscopic Colectomy Completed NCT02248246 Phase 4
36 Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients Completed NCT00966277 Phase 4 Dalteparin
37 Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions Completed NCT00029224 Phase 4 zoledronic acid
38 Preoperative Transarterial Chemoembolization for Resectable HCC With Portal Venous Invasion Completed NCT01952353 Phase 4
39 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
40 Resection vs. Best Supportive Care for Hepatocellular Carcinoma (HCC) With Portal Venous Thrombus Completed NCT01600196 Phase 4
41 A Pilot Study to Evaluate Efficacy and Safety of Clevidipine in Neurosurgical Patients Completed NCT00952081 Phase 4 Clevidipine
42 Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis Completed NCT00646100 Phase 4
43 Novel MRI Strategies as a Non-invasive Biomarker in Women With Uterine Fibroids Completed NCT00746031 Phase 4 GnRH analogue (Zoladex);GnRH antagonist-Cetrorelix
44 Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases Completed NCT00434447 Phase 4 Zoledronic acid
45 INVEST: INternational VErapamil SR Trandolapril STudy Completed NCT00133692 Phase 4 Verapamil SR/Trandolapril/Hydrochlorothiazide (HCTZ);Atenolol/HCTZ/Trandolapril
46 Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration Completed NCT00504959 Phase 4 ranibizumab
47 Retrospective Survey of Re-treatment With Bortezomib Completed NCT01524445 Phase 4
48 Phase IV Bioseal Study in Brain Tumor Surgery Completed NCT02034799 Phase 4
49 Effects of Dexmedetomidine on the Liver Injury After Hepatectomy Completed NCT02833688 Phase 4 dexmedetomidine;0.9% sodium chloride
50 Observational Study in Participants With Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL) in Latin America Completed NCT02559583 Phase 4

Search NIH Clinical Center for Vascular Cancer

Cochrane evidence based reviews: vascular neoplasms

Genetic Tests for Vascular Cancer

Anatomical Context for Vascular Cancer

MalaCards organs/tissues related to Vascular Cancer:

39
Lung, Bone, Liver, Prostate, Brain, Bone Marrow, T Cells

Publications for Vascular Cancer

Articles related to Vascular Cancer:

id Title Authors Year
1
Research gives hope to patients with rare vascular cancer. Cleveland Clinic researchers suggest that their work could lead to breakthrough in treating other cancers. ( 22272406 )
2011
2
New strategies in anti-vascular cancer therapy. ( 10469169 )
1999
3
Anti-vascular cancer therapy: is it a dream or reality? ( 1720044 )
1991

Variations for Vascular Cancer

Expression for Vascular Cancer

Search GEO for disease gene expression data for Vascular Cancer.

Pathways for Vascular Cancer

Pathways related to Vascular Cancer according to GeneCards Suite gene sharing:

(show all 39)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.44 FGF2 FLT1 FLT4 KDR KIT PDGFRB
2
Show member pathways
13.3 FGF2 FLT1 FLT4 KDR KIT PDGFRB
3
Show member pathways
13.22 FGF2 FLT1 FLT4 KDR KIT PDGFRB
4
Show member pathways
13.19 FGF2 FLT1 FLT4 KDR KIT PDGFRB
5
Show member pathways
13.15 FGF2 FLT1 FLT4 KDR KIT PDGFRB
6
Show member pathways
12.97 FGF2 FLT1 FLT4 KDR KIT PDGFRB
7
Show member pathways
12.94 FGF2 FLT1 FLT4 KDR KIT PDGFRB
8
Show member pathways
12.89 FLT1 FLT4 KDR KIT PDGFRB
9
Show member pathways
12.74 FLT1 FLT4 KDR PDGFRB THBS1 VEGFA
10
Show member pathways
12.59 FGF2 FLT1 FLT4 KDR
11 12.57 FGF2 KIT PDGFRB VEGFA
12
Show member pathways
12.46 FGF2 FLT4 KDR KIT PDGFRB VEGFA
13
Show member pathways
12.41 FLT1 FLT4 KDR PDGFRB
14
Show member pathways
12.4 FGF2 FLT1 FLT4 KDR KIT PDGFRB
15
Show member pathways
12.36 FLT1 FLT4 KDR PDGFRB
16
Show member pathways
12.29 FLT1 FLT4 KDR VEGFA
17
Show member pathways
12.27 FGF2 FLT1 FLT4 KDR VEGFA
18 12.23 FGF2 KDR THBS1 VEGFA
19
Show member pathways
12.16 FLT1 FLT4 KDR PDGFRB
20
Show member pathways
12.15 FGF2 FLT1 KDR VEGFA
21 12.14 FGF2 FLT1 FLT4 KDR KIT PDGFRB
22
Show member pathways
12.03 KDR THBS1 VWF
23 11.96 FGF2 KDR PDGFRB VEGFA
24 11.91 ANPEP ENG KIT
25
Show member pathways
11.89 FLT1 KDR PDGFRB VEGFA
26 11.89 FGF2 FLT1 FLT4 KDR KIT PDGFRB
27 11.8 ENG FGF2 KIT
28
Show member pathways
11.74 FLT1 FLT4 KDR VEGFA
29
Show member pathways
11.69 FLT1 FLT4 KDR KIT PDGFRB
30
Show member pathways
11.57 FLT1 FLT4 KDR KIT PDGFRB
31 11.48 FGF2 KDR VEGFA
32 11.48 ANPEP FGF2 KDR KIT
33 11.45 FGF2 KIT VEGFA
34 11.41 FGF2 KDR VEGFA
35
Show member pathways
11.37 KDR PDGFRB VEGFA
36 11.26 FLT1 KDR VEGFA
37 11.16 ENG FGF2 FLT1 FLT4 KDR PDGFRB
38 11.1 FGF2 FLT1 VEGFA
39 11.09 FGF2 FLT1 KDR VEGFA

GO Terms for Vascular Cancer

Cellular components related to Vascular Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.92 FGF2 FLT1 FLT4 HBA1 KDR THBS1
2 receptor complex GO:0043235 9.58 ENG FLT1 FLT4
3 external side of plasma membrane GO:0009897 9.56 ANPEP ENG KIT THBS1
4 cell surface GO:0009986 9.55 ENG KIT PDGFRB THBS1 VEGFA
5 platelet alpha granule GO:0031091 9.37 THBS1 VWF
6 extracellular space GO:0005615 9.23 ANPEP ENG FGF2 FLT1 HBA1 KIT
7 platelet alpha granule lumen GO:0031093 9.13 THBS1 VEGFA VWF

Biological processes related to Vascular Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 51)
id Name GO ID Score Top Affiliating Genes
1 extracellular matrix organization GO:0030198 9.93 FGF2 KDR THBS1 VWF
2 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.93 FGF2 FLT4 KDR PDGFRB
3 protein autophosphorylation GO:0046777 9.92 FLT1 FLT4 KDR KIT PDGFRB
4 positive regulation of protein phosphorylation GO:0001934 9.91 ENG FLT4 KDR VEGFA
5 positive regulation of cell migration GO:0030335 9.91 FLT1 KDR KIT PDGFRB THBS1 VEGFA
6 chemotaxis GO:0006935 9.89 FGF2 FLT1 PDGFRB
7 regulation of cell shape GO:0008360 9.88 KDR KIT VEGFA
8 positive regulation of MAPK cascade GO:0043410 9.88 FLT1 FLT4 KDR KIT
9 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.88 FLT1 FLT4 KDR KIT PDGFRB
10 platelet degranulation GO:0002576 9.87 THBS1 VEGFA VWF
11 phosphatidylinositol-mediated signaling GO:0048015 9.86 FGF2 KIT PDGFRB
12 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.86 FLT1 FLT4 KDR VEGFA
13 positive regulation of cell proliferation GO:0008284 9.86 FGF2 FLT1 FLT4 KDR KIT PDGFRB
14 activation of MAPK activity GO:0000187 9.85 FGF2 KIT THBS1
15 phosphatidylinositol phosphorylation GO:0046854 9.85 FGF2 KIT PDGFRB
16 positive regulation of endothelial cell proliferation GO:0001938 9.85 FGF2 FLT4 KDR VEGFA
17 peptidyl-tyrosine phosphorylation GO:0018108 9.85 FGF2 FLT1 FLT4 KDR KIT PDGFRB
18 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.84 FLT1 KDR KIT PDGFRB
19 regulation of phosphatidylinositol 3-kinase signaling GO:0014066 9.83 FGF2 KIT PDGFRB
20 vasculogenesis GO:0001570 9.81 ENG KDR VEGFA
21 positive regulation of endothelial cell migration GO:0010595 9.81 FLT4 KDR THBS1 VEGFA
22 sprouting angiogenesis GO:0002040 9.77 ENG FLT4 THBS1
23 positive regulation of blood vessel endothelial cell migration GO:0043536 9.76 FGF2 THBS1 VEGFA
24 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 9.76 FGF2 FLT1 KIT PDGFRB
25 cell migration involved in sprouting angiogenesis GO:0002042 9.74 FGF2 KDR VEGFA
26 positive regulation of MAP kinase activity GO:0043406 9.72 FGF2 FLT1 KIT PDGFRB VEGFA
27 positive regulation of focal adhesion assembly GO:0051894 9.71 KDR VEGFA
28 positive regulation of collagen biosynthetic process GO:0032967 9.71 ENG PDGFRB
29 cellular response to vascular endothelial growth factor stimulus GO:0035924 9.71 FLT1 FLT4 KDR VEGFA
30 artery morphogenesis GO:0048844 9.7 ENG VEGFA
31 negative regulation of blood vessel endothelial cell migration GO:0043537 9.7 FGF2 THBS1
32 megakaryocyte development GO:0035855 9.69 FLI1 KIT
33 embryonic morphogenesis GO:0048598 9.69 FGF2 FLT1
34 embryonic hemopoiesis GO:0035162 9.69 KDR KIT
35 positive regulation of vascular endothelial growth factor receptor signaling pathway GO:0030949 9.68 FLT1 VEGFA
36 positive regulation of positive chemotaxis GO:0050927 9.67 KDR VEGFA
37 vascular endothelial growth factor signaling pathway GO:0038084 9.67 FLT1 FLT4 KDR
38 positive regulation of chemotaxis GO:0050921 9.66 PDGFRB THBS1
39 positive regulation of protein kinase C signaling GO:0090037 9.65 FLT4 VEGFA
40 positive regulation of angiogenesis GO:0045766 9.63 ENG FGF2 FLT1 KDR THBS1 VEGFA
41 positive regulation of vascular smooth muscle cell differentiation GO:1905065 9.62 ENG KIT
42 regulation of cGMP metabolic process GO:0030823 9.62 THBS1 VEGFA
43 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.61 KDR VEGFA
44 positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway GO:0038091 9.6 PDGFRB VEGFA
45 angiogenesis GO:0001525 9.5 ANPEP ENG FGF2 FLT1 FLT4 KDR
46 positive regulation of phospholipase C activity GO:0010863 8.92 FGF2 FLT1 KIT PDGFRB
47 multicellular organism development GO:0007275 10.15 ANPEP FGF2 FLT1 KDR PDGFRB VEGFA
48 cell differentiation GO:0030154 10.12 ANPEP FGF2 FLI1 FLT1 KDR VEGFA
49 phosphorylation GO:0016310 10.08 FLT1 FLT4 KDR KIT PDGFRB
50 protein phosphorylation GO:0006468 10.06 FLT1 FLT4 KDR KIT PDGFRB

Molecular functions related to Vascular Cancer according to GeneCards Suite gene sharing:

(show all 14)
id Name GO ID Score Top Affiliating Genes
1 kinase activity GO:0016301 9.88 FLT1 FLT4 KDR KIT PDGFRB
2 protein homodimerization activity GO:0042803 9.83 ENG KIT VEGFA VWF
3 protein kinase activity GO:0004672 9.77 FLT1 FLT4 KDR KIT PDGFRB
4 heparin binding GO:0008201 9.71 FGF2 THBS1 VEGFA
5 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.67 FGF2 KIT PDGFRB
6 integrin binding GO:0005178 9.61 KDR THBS1 VWF
7 transforming growth factor beta binding GO:0050431 9.51 ENG THBS1
8 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.5 FGF2 KIT PDGFRB
9 platelet-derived growth factor receptor binding GO:0005161 9.46 PDGFRB VEGFA
10 growth factor binding GO:0019838 9.43 FLT1 FLT4 KDR
11 protein tyrosine kinase activity GO:0004713 9.43 FGF2 FLT1 FLT4 KDR KIT PDGFRB
12 signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 9.4 KDR KIT
13 vascular endothelial growth factor-activated receptor activity GO:0005021 9.33 FLT1 FLT4 KDR
14 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.02 FLT1 FLT4 KDR KIT PDGFRB

Sources for Vascular Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....